Valuation: FamiCord AG

Market Cap 54.04M 60.82M 50.44M 45.97M 86.7M 5.85B 87.51M 610M 237M 2.99B 228M 223M 9.59B P/E 2026 *
310x
P/E 2027 * 51.7x
Enterprise Value 62.04M 69.82M 57.9M 52.78M 99.54M 6.71B 100M 701M 272M 3.43B 262M 256M 11.01B EV / Sales 2026 *
0.73x
EV / Sales 2027 * 0.68x
Free-Float
26.82%
Yield 2026 *
-
Yield 2027 * -
1 week+3.81%
Current month+3.81%
1 month+4.17%
3 months-15.49%
6 months-35.34%
Current year-49.15%
1 week 2.74
Extreme 2.74
3.08
1 month 2.74
Extreme 2.74
3.08
3 years 2.56
Extreme 2.56
7.5
5 years 2.56
Extreme 2.56
17.4
10 years 2.56
Extreme 2.56
17.8
Manager TitleAgeSince
Chief Executive Officer 55 21/03/2022
Director of Finance/CFO 53 31/07/2024
Chief Tech/Sci/R&D Officer - 28/02/2025
Director TitleAgeSince
Chairman 62 27/06/2017
Director/Board Member - 31/12/2016
Director/Board Member 54 30/11/2021
Change 5-day change 1-year change 3-year change Capi.($)
+9.49%+3.81%-48.72%-34.50% 60.82M
+1.48%-3.00%+11.58%+25.34% 111B
+0.78%-2.05%-0.66%+75.33% 92.38B
+0.46%-0.54%+145.20%+850.76% 59.15B
-0.38%-5.45%-7.47%+56.12% 27.66B
+0.97%-1.27%+30.11%+90.35% 25.75B
+1.28%-0.37%+11.39%+53.28% 25.02B
-0.67%+0.31%-16.34%-4.81% 20.99B
+1.83%-0.42%+27.40%+322.31% 20.82B
-0.77%-3.25%-7.19%+33.16% 16.87B
Average +0.57%-1.83%+14.53%+146.73% 44.36B
Weighted average by Cap. +0.81%-2.05%+26.96%+181.48%

Financials

2026 *2027 *
Net sales 85M 95.67M 79.33M 72.31M 136M 9.2B 138M 960M 372M 4.7B 359M 351M 15.09B 88.4M 99.49M 82.51M 75.2M 142M 9.56B 143M 998M 387M 4.89B 374M 365M 15.69B
Net income 300K 338K 280K 255K 481K 32.46M 486K 3.39M 1.31M 16.59M 1.27M 1.24M 53.25M 1M 1.13M 933K 851K 1.6M 108M 1.62M 11.3M 4.38M 55.31M 4.23M 4.13M 178M
Net Debt 8M 9M 7.47M 6.81M 12.84M 866M 12.95M 90.36M 35.01M 442M 33.81M 33.07M 1.42B 6M 6.75M 5.6M 5.1M 9.63M 649M 9.72M 67.77M 26.26M 332M 25.35M 24.8M 1.07B
Logo FamiCord AG
FamiCord AG, formerly Vita 34 AG, is a Germany-based company operating in the medical technology sector and acts as a cell bank/stem bank. The Company is involved in the long-term storage and processing of stem cells from human umbilical cord blood. The cells are collected during the child’s birth and can be used later in his or her life for the treatment of many diseases, such as anemia, diabetes, degenerative joint diseases, cancer, neurological deficits after brain injuries, cartilage damages and others. The cells also allow the growing of whole organs, such as the liver. On an average, one out of seven individuals, whose cells are sorted, receives autologous stem cell transplant by age of 70. The Company acts as a cord blood bank and is also engaged in research activities around regenerative medicine, including curing the consequences of strokes and heart attacks. The Company operates in Germany, Spain and Denmark.
Employees
-
Date Price Change
02/10/26 €3.000 +9.49%
01/10/26 €2.740 -5.19%
30/09/26 €2.890 0.00%
29/09/26 €2.890 0.00%
28/09/26 €2.890 0.00%
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
3.100EUR
Average target price
6.500EUR
Spread / Average Target
+109.68%

Annual profits - Rate of surprise